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Opioid epidemic in the USA
Data from Malaysia








Kulliyyah of Pharmacy IIUM |  Seminar Lahore University
02
Opioid history
• Friedrich Wilhelm Serturner
• German pharmacist
• Isolated Morphine in 1803 and 









• Cancer pain 
• Acute pain 
• Post surgical pain 
Controversy 








Opioid prescriptions  increased tremendously

• Increase in opioid 
sales is parallel with 
the increase in opioid 
deaths
CDC (Cent.Dis.Control Prev.). 2011. Vital signs: 
overdoses of prescription opioid pain relievers—





• worst drug overdose 
epidemic in US history
50%
Source of opioids
Among those receiving the opioid prescriptions
60% of deaths occurred in patients receiving 
prescriptions based on prescribing guidelines by medical 
boards 
40% of deaths occurred in individuals with substance use 
disorders who obtained opioids through multiple 
prescriptions, doctor shopping, and drug diversion.

Drug dealers are no longer the 
primary source of illicit drugs. 
Our greatest enemy is now 
inappropriate prescribing 
patterns  




how they get 
there..
• About 20 years ago, 
• compassionate advocacy for better 
treatment of chronic pain
• aggressive marketing of opioid formulations 
• led to a sharp increase in the prescribing of 
opioid analgesics for patients with chronic 
noncancer pain(CNCP) in most developed 
countries. 






People at higher risk of opioid overdose 
death 
❑ High doses  of opioid
❑Concurrent use/co-medications of opioids 




50–99 mg/day (3.7- fold increase 
in overdose risk)
>100 mg/day (8.9-fold increase in 
overdose risk)
Compared to 1-20 mg/day
Dunn et al., 2010
Co-medications
It was also reported that the risk of overdose death was increased 
15-fold in patients filling both opioid and benzodiazepine prescriptions 
compared with those filling neither prescription




Let’s look at our local data
1. Dose and duration of opioid use
Zin et.al.,Pain Practice 2016
Outpatient opioid prescriptions from 2013- 2014
Patient level opioid use
1015 opioid prescriptions for 347 patients
Patients and methods
Opioid dose in oral morphine equivalents(OMEQ)
OMEQ = 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝑜𝑝𝑖𝑜𝑖𝑑 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 × 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ 𝑚𝑔
× 𝐸𝑞𝑢𝑖𝑎𝑛𝑎𝑙𝑔𝑒𝑠𝑖𝑐 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑜𝑝𝑖𝑜𝑖𝑑
Total OMEQ per 
patient   
= 𝑆𝑢𝑚 𝑜𝑓 𝑂𝑀𝐸𝑄 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 𝑎 𝑝𝑎𝑟𝑡𝑖𝑐𝑢𝑙𝑎𝑟 𝑦𝑒𝑎𝑟
Dose per day =
𝑇𝑜𝑡𝑎𝑙 𝑂𝑀𝐸𝑄 𝑑𝑜𝑠𝑒 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑎 𝑝𝑎𝑟𝑡𝑖𝑐𝑢𝑙𝑎𝑟 𝑦𝑒𝑎𝑟
𝑇𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠 𝑜𝑓 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑎 𝑝𝑎𝑟𝑡𝑐𝑖𝑢𝑙𝑎𝑟 𝑦𝑒𝑎𝑟
Days of Supply
𝐃𝐚𝐲𝐬 𝐨𝐟 𝐬𝐮𝐩𝐩𝐥𝐲 =
𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑠𝑢𝑝𝑝𝑙𝑦 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒
• Total days supply per patient during a particular year were calculated by adding the days supply of
each prescription prescribed for a particular patient during the year.
• The overlapping days between the prescriptions for each patient were subtracted from the total days




Opioid prescriptions issued for patients with cancer and non-
cancer
Non-cancer Cancer 




































Type of opioids in cancer and non-cancer
Cancer
Non-cancer

























Age categories (years old)
Cancer
Non-cancer 
Age categories in cancer and non-cancer

































A majority of patients in both cancer and 
noncancer groups  < 50 mg/day 
About 5% of noncancer-high-dose opioid therapy 
of > 100 mg/day
Mean opioid dose/day per patient





















Mean total days covered with opioid per patients
The chronic use of opioids (> 90 days per 
year) was associated with 21.8% of 
patients in the noncancer group and 
17.5% in the cancer group.
Zin et. Al., Pain Practice 2016
Main findings
• ~40% for non-cancer pain and ~60% for cancer pain
• Oxycodone was the most prescribed for non-cancer pain
• A majority of patients were prescribed  < 50 mg/day 
• ~5% of patients with noncancer pain –high dose opioid therapy of > 
100 mg/day
• Chronic use of opioids in 21.8% (non-cancer group) and 17.5% 
(cancer group)
The patterns of opioid use in patients with noncancer
pain  were similar
to those found in other studies 
2. Co-medications

Outpatient opioid prescriptions from 2013- 2014
Patient level opioid use













OP+OP OP+AC OP+BZD OP+AD Others 2
OP+BZD+AD OP+AC+AD OP+BZD+AC Others 3 Others >3
Combination 2
Combination 3
Co-prescriptions of opioid with benzodiazepines 
and other co-medications The co-prescriptions
of opioid with 
benzodiazepine were 
prescribed to 12.3% of 
patients,





















































































































































































Type of drug in each category




















































































































































































Mean opioid dose/day per patients and number 
of patients for each combination The individual opioid
dose in the co-prescription was 
moderate and was  within the 
recommended dose. The highest 
opioid dose was in the combination 
of opioid + anticonvulsant + 
antidepressant
Zin et.al.,Pain Practice 2016
Main findings
• 12.3%  of patients received co-prescriptions of opioid + 
benzodiazepine
• Dose of opioid in this combination  31 to 66 mg/day
• Tramadol and alprazolam was the main combination of opioid and 
BZD
• For controlled drug (oxycodone and alprazolam) the main 
combination
• The overall findings on the use of co-medications in this study reflect 
the prevalence of comorbidities and more severe pain among opioid 
users, and this biopsychosocial issue of chronic pain requires 
comprehensive approaches involving multidisciplinary pain 
management team
• In view of safety concerns with certain co-prescriptions, those who 
were using opioids with benzodiazepines appear to represent a 
particularly high-risk group.
3. Patterns of initial opioid prescribing 

• Patient level opioid use
• Age >18 years with at least with one opioid prescription
• 2011-2016
• 33752 opioid naïve patients who received 43432 opioid prescriptions
• Opioid naïve patients (had no opioid prescriptions in the 365 days prior the 





























Short term Long term
Fig 1 Dose per day and day supply per patient in patients who 
became short or long term users after the initiation of opioid
Dose/day and day supply in patients who became 
































Short Term Long Term
Fig 2 Department issuing the opioid and formulation of opioid during 
the initial prescription in patients who became short term and long 
term opioid users.   
Formulation and department
• 11.6% of opioid-naïve patients became long-term opioid users in the 
subsequent 365 days after receiving their initial opioid prescription in 
a Malaysian tertiary hospital setting. 
Main findings 
Main findings 
• During the initial opioid prescription, 
• Short-term opioid users were predominantly prescribed opioids 
• For 3–7 days (59.06%) 
• by the emergency department (ED, 60.56%), 
• Long-term opioid users were primarily prescribed opioids
• For ≥7 days (91.85%) by 
• By non-ED hospital departments (91.8%). 
• Factors associated with long-term opioid use: 
• increasing opioid daily doses, prescription period ≥7 days and long-acting 
opioids initiated by non-EDs 
• CDC recommends the use of opioid therapy for ≤3 days, and 
states that therapy for >7 days is seldom required 
• Because treatment for acute pain often leads to long-term 
opioid use 
Edlund MJ et al  Clin J Pain 2014;30:557–64. 
Dowell D et al .JAMA 2016;315:1624–45. 
• Information regarding the high-risk characteristics of initial opioid 
prescriptions is important as acute opioid therapy can quickly 
progress to long-term use. This information may help clinicians to 
have greater control over opioid prescriptions to mitigate the 
chances of unintentional chronic use of opioids. 
4. Opioid dose escalation  

Patients and methods
• Retrospective cohort study  
• Opioid naïve patients, aged ≥18 years, who were undergoing long-term 
opioid therapy of ≥90 days, with at least one opioid prescription  
• 1st January 2011 and 31st December 2016    
• They were followed until (i) the end of the study period, (ii) death from any 
cause or (iii) discontinuation of therapy from their first opioid prescription 
without any intervals of ≥120 days between successive prescriptions.  
• A total of 4688 patients (58.8% women, 41.3% men) on long-term opioid 
therapy were identified. 
Figure 1. Kaplan-Meier curves of high opioid dose escalation to an average daily dose 
exceeding 100 mg of morphine (or equivalent) among men and women
Main findings
• Among long term opioid users, 248 (5.29%) were escalated to high 
opioid doses of ≥100 mg/day and 69 (1.47%) were escalated to ≥200 
mg/day. 
• female patients were prescribed long-term opioid therapy more 
frequently than men 
• The risk of high-dose opioid escalation was more likely to occur in 
men than in women
Among the patients with long-term opioid therapy, men are at higher risk of high 
dose escalation of opioid compared to women. Opioid related morbidity and 
mortality can be prevented by understanding the different risk associated with 
prescription opioid use by sex differences. Further research is needed to 
identify other risks of opioid related harms and its related outcomes in order to 
stratify the risk. Such an endeavour can be an effort towards minimising the 
unwanted consequences of opioid therapy
5. Overall  analgesic use

Patients and methods
• Cross-sectional study was conducted from 2010 to 2016 using the prescription 
databases of two tertiary hospitals in Malaysia.
• Prescriptions for nine NSAIDs (ketoprofen, diclofenac, celecoxib, etoricoxib, 
ibuprofen, indomethacin, meloxicam, mefenamic acid, and naproxen), tramadol, 
and five other opioids (morphine, fentanyl, oxycodone, dihy- drocodeine, and 
buprenorphine) were included in this study.  
• 192,747 analgesic prescriptions of the nine NSAIDs, tramadol, and five other opioids 
were given for 97,227 patients 




• Tramadol has been the most frequently prescribed analgesic at 
outpatient hospital settings in Malaysia. 
• The prescriptions for NSAIDs were primarily for ketoprofen, 
diclofenac, and celecoxib, whereas the opioids predominantly 
prescribed were morphine and oxycodone. 
• The overall utilization of analgesics in Malaysia has increased steadily, 
with opioid utilization increasing at a greater rate 



















• Should be protected from similar negative outcomes. 
• Education on opioids
• Rational use of opioids  
Thank you
• chesuraya@iium.edu.my
